1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Myasthenia Gravis Treatment Market
2.3. Global Myasthenia Gravis Treatment Market, By Treatment Type, 2025 (US$ Million)
2.4. Global Myasthenia Gravis Treatment Market, By End-Use, 2025 (US$ Million)
2.5. Global Myasthenia Gravis Treatment Market, By Geography, 2025 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2025
3. Myasthenia Gravis Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Myasthenia Gravis Treatment Market Vendors
3.2. Strategies Adopted by Myasthenia Gravis Treatment Market Vendors
4. Myasthenia Gravis Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Myasthenia Gravis Treatment Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape
5. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Cholinesterase Inhibitors
5.3.2. Chronic Immunomodulators
5.3.3. Monoclonal Antibodies
5.3.4. Rapid Immunotherapies
5.3.5. Thymectomy
5.3.6. Others
6. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2025 Versus 2034
6.3. Market Segmentation
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
7. North America Myasthenia Gravis Treatment Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
7.3. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
7.4. Myasthenia Gravis Treatment Market: By Region, 2024-2034, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
7.4.1.1.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
7.4.1.2.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
7.4.1.3.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
8. UK and European Union Myasthenia Gravis Treatment Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
8.3. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
8.4. Myasthenia Gravis Treatment Market: By Region, 2024-2034, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
8.4.1.1.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
8.4.1.2.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
8.4.1.3.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
8.4.1.4.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
8.4.1.5. France
8.4.1.5.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
8.4.1.5.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
8.4.1.6.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
9. Asia Pacific Myasthenia Gravis Treatment Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
9.3. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
9.4. Myasthenia Gravis Treatment Market: By Region, 2024-2034, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
9.4.1.1.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
9.4.1.2.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
9.4.1.3. India
9.4.1.3.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
9.4.1.3.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
9.4.1.4.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
9.4.1.5.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
9.4.1.6.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
10. Latin America Myasthenia Gravis Treatment Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
10.3. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
10.4. Myasthenia Gravis Treatment Market: By Region, 2024-2034, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
10.4.1.1.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
10.4.1.2.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
10.4.1.3.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
11. Middle East and Africa Myasthenia Gravis Treatment Market, 2024-2034, USD (Million)
11.1. Market Overview
11.2. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
11.3. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
11.4. Myasthenia Gravis Treatment Market: By Region, 2024-2034, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
11.4.1.1.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
11.4.1.2.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Myasthenia Gravis Treatment Market: By Treatment Type, 2024-2034, USD (Million)
11.4.1.3.2. Myasthenia Gravis Treatment Market: By End-Use, 2024-2034, USD (Million)
12. Company Profile
12.1. Alexion Pharmaceutical Inc. (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
12.2. Grifols SA
12.3. Avadel Pharmaceuticals plc.
12.4. Novartis AG
12.5. Pfizer, Inc.
12.6. AbbVie Inc.
12.7. F. Hoffmann-La Roche Ltd.
12.8. GlaxoSmithKline plc
12.9. Bausch Health Companies Inc.
12.10. Shire plc
12.11. Other Notable Players
